MolDX: DecisionDx-UM (Uveal Melanoma)

DecisionDx-UM testing is covered for management of newly diagnosed uveal melanoma patients who have a confirmed diagnosis and no evidence of metastatic disease. The test is intended to determine metastatic risk and to guide surveillance and referral to medical oncology (preferably a melanoma specialist). Documentation should demonstrate the diagnosed uveal melanoma, absence of metastasis, and clinical intent to use test results for management decisions.

"DecisionDx-UM test (Castle Bioscience) is covered for management of newly diagnosed uveal melanoma."

Sign up to see full coverage criteria, indications, and limitations.